Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome

IMPORTANCE: Olmsted syndrome is a rare and disabling genodermatosis for which no successful treatment is currently available. OBJECTIVE: To evaluate the clinical response to the mammalian target of rapamycin (mTOR) inhibitor sirolimus and/or the epidermal growth factor receptor (EGFR) inhibitor erlo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Dermatol
Main Authors: Zhang, April, Duchatelet, Sabine, Lakdawala, Nikita, Tower, Richard L., Diamond, Carrie, Marathe, Kalyani, Hill, India, Richard, Gabriele, Diab, Yaser, Kirkorian, Anna Yasmine, Watanabe, Flora, Siegel, Dawn H., Hovnanian, Alain
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990762/
https://ncbi.nlm.nih.gov/pubmed/31895414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2019.4141
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados